Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Aharona Glatman-Freedman; Yael Hershkovitz; Zalman Kaufman; Rita Dichtiar; Lital Keinan-Boker; Michal Bromberg

doi:10.3201/eid2711.211886

Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Aharona Glatman-Freedman
, Yael Hershkovitz
, Zalman Kaufman
, Rita Dichtiar
, Lital Keinan-Boker
, Michal Bromberg

School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

Original language	English
Pages (from-to)	2919-2922
Number of pages	4
Journal	Emerging Infectious Diseases
Volume	27
Issue number	11
DOIs	https://doi.org/10.3201/eid2711.211886
State	Published - Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 Centers for Disease Control and Prevention (CDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Epidemiology
Microbiology (medical)
Infectious Diseases

Access to Document

10.3201/eid2711.211886

Cite this

@article{cd12392236b845bcaac599959ebd55be,

title = "Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021",

abstract = "In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.",

author = "Aharona Glatman-Freedman and Yael Hershkovitz and Zalman Kaufman and Rita Dichtiar and Lital Keinan-Boker and Michal Bromberg",

year = "2021",

month = nov,

doi = "10.3201/eid2711.211886",

language = "English",

volume = "27",

pages = "2919--2922",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "11",

}

TY - JOUR

T1 - Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

AU - Glatman-Freedman, Aharona

AU - Hershkovitz, Yael

AU - Kaufman, Zalman

AU - Dichtiar, Rita

AU - Keinan-Boker, Lital

AU - Bromberg, Michal

PY - 2021/11

Y1 - 2021/11

N2 - In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

AB - In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant-dominant infection. We evaluated short-term vaccine eff ectiveness and found the vaccine to be highly eff ective among this population in this setting.

UR - https://www.scopus.com/pages/publications/85117942942

U2 - 10.3201/eid2711.211886

DO - 10.3201/eid2711.211886

M3 - Article

C2 - 34570694

AN - SCOPUS:85117942942

SN - 1080-6040

VL - 27

SP - 2919

EP - 2922

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 11

ER -

Effectiveness of bnt162b2 vaccine in adolescents during outbreak of sars-cov-2 delta variant infection, israel, 2021

Abstract

Bibliographical note

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this